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According to the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO) 
definition, probiotics are live microorganisms, which when administered in adequate amount confer a health benefit on the 
host. The Polish Society for Probiotics and Prebiotics is strongly advocating this definition and the safety aspects that 
FAO/WHO stress.
The fact that many beneficial microorganisms have a long history of safe use in a large population and are generally 
considered as safe, as well as that most studies do not show any adverse events related to probiotics may have been 
shaken by some recently available data, primarily owing to the publicity related to PROPATRIA (PRObiotics in PAncreatitis 
TRIAI) study in the Netherlands. The statement released by the International Scientific Association for Probiotics and 
Prebiotics following the results of this Dutch study lists some very important conclusions, questions some aspects of study 
and calls to the scientific community to use the term probiotic only if appropriate criteria are met, but probably one single 
point from these conclusions will be vital for future clinical trials on probiotics, i.e. establishment of safety of the approach 
when treating vulnerable patients, especially research to define proper animal models of safety. The table below lists some 
recent studies described in the literature and their outcomes:
Table 1. Recently published studies on microbes with clinical applications and their unexpected outcomes.
Published study Patient groups Condition Strains & doses Results Conclusions
Probiotic prophylaxis in 
predicted severe acute 
pancreatitis:
a randomised, double-blind, 
placebo-controlled trial
Lancet 2008;371:651-9.
Probiotics group n=152 
and
placebo group n=144
acute pancreatitis
Ecologic 641 (Lactobacillus 
acidophilus, L  casei,
L. salivarius, Lactococcus 
lactis, Bifidobacterium bifidum, 
and B. lactis).
Total daily dose of 1010 bacteria 
given via nasojejunal tube.
Infectious complications: 46 in 
probiotics group vs. 41 control 
(none by administered strains). 
Bowel ischaemia: 9 in probiotics 
group vs. 0 control.
Deaths: 24 in probiotics group 
vs. 9 control.
Speculated mechanism o f bowel ischaemia: 
increased local oxygen demand to already 
critically reduced blood flow  or local 
inflammation at the mucosal level? 
“ ...probiotic prophylaxis with this combination 
of probiotic strains did not reduce the risk o f 
infectious complications and was associated 
with an increased risk of mortality. Probiotic 
prophylaxis should therefore not be 
administered in this category o f patients."
Randomized, double-blind, 
placebo-controlled trial of 
probiotics for primary 
prevention: no clinical 
effects of Lactobacillus GG 
supplementation 
Pediatrics 2008; 121 :e850-6.
Probiotics group n=50 
and
placebo group n=44
atopic dermatitis
Atopic dermatitis: 14 in probiotic 
Lactobacillus GG (American group vs. 12 control 
Type Culture Collection 53103). (comparable severity).
5x10® colony-forming units twice Recurrent episodes of wheezing 
daily p e r os. bronchitis: 13 in probiotics group 
vs. 4 control.
"Supplementation with Lactobacillus  GG 
during pregnancy and early infancy neither 
reduced the incidence of atopic dermatitis 
nor altered the severity o f atopic dermatitis in 
affected children but was associated w ith an 
increased rate o f recurrent episodes of 
wheezing bronchitis. Therefore,
Lactobacillus  GG cannot be generally 
recommended fo r primary prevention."
Probiotic supplementation for 
the first 6 months of life fails 
to reduce the risk of atopic 
dermatitis and increases the 
risk of allergen sensitization in 
high-risk children: 
a randomized controlled trial 
J Ailergy Clin Immunol 2007; 
119:184-91.
Probiotics group n=89 
and
placebo group n=89
atopic dermatitis
Lactobacillus acidophilus 
LAVRI-A1.
3x109 L. acidophilus LAVRI-A1 
daily per os.
Atopic dermatitis: 23 in probiotic 
group vs. 20 control 
(comparable severity).
At 12 months, the rate of 
sensitization was significantly 
higher in the probiotic group 
(p =0.030).
“Early probiotic supplementation with 
L  acidophilus did not reduce the risk o f AD 
in high-risk infants and was associated with 
increased allergen sensitization in infants 
receiving supplements. The long-term 
significance of the increased rate of 
sensitization needs to be investigated in 
fu rther studies. These findings challenge the 
role o f probiotics in allergy prevention.”
Discussion: There are documented situations in the literature when the use of microbial products has resulted in 
unexpected outcomes, contrary to what the authors have actually hypothesized. There are also reports in the literature of 
infections caused by genera that are usually considered beneficial. Moreover, only little is known about the immunological 
mechanisms of action of probiotics and their effects are probably strain-specific. Experts agree that probiotics are used on a 
very large scale and basically show no adverse events, but looking further, not many probiotic strains have documented 
randomized, double blind, placebo-controlled trials on large populations showing their safety in special situations, e.g. in 
chronically ill or severely immunocompromised subjects. The studies described show different dosages as well as modes 
of administration, that may play a role in the hypothetical "overdosing” of the bacteria and have an indirect influence on 
adverse events (and not being the isolated agent of infection).
Conclusions: Does the future hold any more surprises and will we see labels on probiotics stating: „ATTENTION! Not to be 
used in the severely ill or immunocompromised"? Can probiotic use show any adverse events at all? And will we see the 
origin of a somewhat controversial, rare condition, namely “probiotic infection”?
Two action items that we should definitely consider in the near future that will improve safety, are:
. Investigation and definition of proper animal safety models, that will enable
. Performance of safety trials on defined animal models, before investigating probiotics in a preferably large, 
multicentre, double-blind randomized placebo-controlled trial settings.
Possible reasons for translocation 
& septic morbidity:
- severe inflammation
- bowel ischaemia
- increased gut 
permeability
- bacterial 
overgrowth
- gut wall 
necrosis
- immune system 
compromise
Figure 1. Probable pathway from gut 
through sepsis to multiple 
organ dysfunction syndrome 
and death.
* Department of Bacteriology, Microbial Ecology and Parasitology, 
Chairof Microbiology, Jagiellonian University Medical College,
18 Czysta Street, 31-121 Cracow, Poland 
b Polish Society for Probiotics and Prebiotics, 18 Czysta Street, 
31-121 Cracow, Poland
References available by request from Piotr Kochan, M.D.
E-mail: pkochan@cm-uj.krakow.pl 
Telephone: +4812 633 25 67 
Fax: +4812 423 39 24
